Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Abstract Text:

Baba,Kathryn Swartz,Regina van Buren,Jens Eickhoff,Yong Zhang,William Wolberg,Andreas Friedl,

Members of the syndecan and glypican families of cell surface heparan sulfate proteoglycans (HSPGs) are modulators of growth factor signaling and cell adhesion. Both loss and gain in expression of syndecans and glypicans has been associated with malignant progression. The goal of this project was to investigate a possible relationship between expression of cell surface HSPGs (syndecan-1, syndecan-4 and glypican-1) and established prognostic factors or clinical outcome in breast carcinomas. Tissue arrays containing 207 human breast carcinoma samples in duplicate were immuno-labeled with antibodies to syndecan-1, syndecan-4, glypican-1, Ki67, E-cadherin, estrogen receptor (ER) and progesterone receptor (PR). Clinical follow-up information was available for up to 18.6 years (median follow-up 6.2 years). Syndecan-1 and syndecan-4 expression in carcinoma cells ranged from complete loss to high expression, but glypican-1 was detected only in a small subset of breast carcinomas. Expression of all three HSPGs was significantly associated with the Ki67 proliferation index (syndecan-1: p=0.0025; syndecan-4: p<0.0001; glypican-1 p=0.01). Syndecan-1 and syndecan-4 expression correlated with ER negativity, grade, and size of the primary tumors. Syndecan-1 expression (but not syndecan-4 nor glypican-1) predicted patient outcome (DFS: p=0.0054; OS: p=0.0086). However, multivariate analysis failed to identify syndecan-1 as an independent prognostic marker, which was due to its significant association with established prognostic factors. The strong association between cell surface HSPGs and the Ki67 proliferation marker would support a biologic role in carcinoma growth regulation. Furthermore, the close correlation between syndecan expression and negative ER status raises the possibility of hormonal regulation or more likely an association with an aggressive, ER-negative carcinoma phenotype.

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Publishing Authors By Initials

F Baba,K Swartz,R van Buren,J Eickhoff,Y Zhang,W Wolberg,A Friedl,

For similar biological factors: biological markers: tumor markers, biological research abstracts see: biological factors: biological markers: tumor markers, biological research

PUBMED ID PMID:

MEDLINE DATE:

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Breast cancer research and treatment

VOLUME: 98

Page Numbers: 91-8

Journal Abbreviation: Breast Cancer Res. Treat.

ISSN: 0167-6806

DAY: 25

MONTH: 04

YEAR: 2006

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8111104

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Keywords Mesh Terms:

KEYWORDS: Tumor Markers, Biological

MESH TERMS: metabolism

Chemical & Substance for Abstract: Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Information

Substance Name: Tumor Markers, Biological

Registry Number: 0

Grant and Affiliation Information for Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.

AFFILIATION: Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53792, USA.

Country: Netherlands

AGENCY: United States NCI

GRANT: R01-CA107012

ACRONYM: CA

MEDLINETA: Breast Cancer Res Treat

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype Related Publications

• Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture.
• Bond strength of adhesive systems to dentin and enamel-Human vs. bovine primary teeth in vitro.
• Competition effect in DNA damage response.
• Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study.
• Glypican-1 regulates anaphase promoting complex/cyclosome substrates and cell cycle progression in endothelial cells.
• High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome.
• Human performance optimization: an evolving charge to the Department of Defense.
• Influence of ceramic translucency on curing efficacy of different light-curing units.
• Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion.
• Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.
• Overexpression of recombinant human antithrombin III in Chinese hamster ovary cells results in malformation and decreased secretion of recombinant protein.
• Somatotrophic Hormonal Responses after U.S. Army Ranger Training and Relationship to Changes in Body Composition: 1402: Board #165 May 30 9:30 AM - 11:00 AM.
• Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
• Transplantation of autologous keratinocyte suspension in fibrin matrix to chronic venous leg ulcers: improved long-term healing after removal of the fibrin carrier.
• [Epidemiology of cancer and the environment]
• [Fracture management during bone growth]
• [Indications, technique, results and value of modified radical mastectomy]
• [Not Available.]
• [The gliding nail. A new implant for complication-free primary load-bearing management of per- and subtrochanteric femoral fractures]